Cover Kidney News
Volume/Issue:
Volume 13: Issue 2
Page:
19
Publication Date:
01 Feb 2021
Online Publication Date:
05 Feb 2021
  • 1.

    Chertow GM, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367:2482−2494. doi: 10.1056/NEJMoa1205624

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Block GA, et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: Two randomized clinical trials. JAMA 2017; 317:146−155. doi: 10.1001/jama.2016.19456

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Block GA, et al. Efficacy and safety of tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: A randomized phase 3 trial. J Am Soc Nephrol 2019; 30:641−652. doi: 10.1681/ASN.2018080832

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Ardelyx Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis. Published December 3, 2019. Accessed December 25, 2020. https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-announces-positive-topline-results-pivotal-phase-3

    • Search Google Scholar
    • Export Citation
  • 5.

    Block GA, et al. A pilot randomized trial of ferric citrate coordination complex for the treatment of advanced CKD. J Am Soc Nephrol 2019; 30:1495−1504. doi: 10.1681/ASN.2018101016

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Edmonston DL, et al. Design and rationale of HiLo: A pragmatic, randomized trial of phosphate management for patients on maintenance hemodialysis. Am J Kidney Dis [published online ahead of print December 3, 2020]. doi: 10.1053/j.ajkd.2020.10.008; https://www.ajkd.org/article/S0272-6386(20)31131-8/fulltext

    • Search Google Scholar
    • Export Citation
  • 7.

    Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE). ClinicalTrials.gov: NCT03573089. https://clinicaltrials.gov/ct2/show/NCT03573089

Editorial Type:
Special Section

Novel Agents in CKD-MBD A Second Lease on Life or Flogging a Dead Horse?

Mayuri Trivedi1 and Sanjeev Nair1
  • 1 Mayuri Trivedi, DM, is assistant professor, Nephrology Services, Department of Medicine, LTMGH, and consultant nephrologist and transplant physician, Hinduja Healthcare Surgical and S L Raheja Fortis Hospital, Mumbai, India. Sanjeev Nair, DM, is associate professor in the Department of Nephrology, Saveetha Medical College and Hospital, Chennai, India.
Volume/Issue:
Volume 13: Issue 2
Publication Date:
01 Feb 2021
Page:
19
Restricted access

Mineral bone disease (MBD) has proven to be a Pandora’s box for most clinicians treating chronic kidney disease (CKD), including end-stage kidney disease (ESKD). Although the body of literature highlighting the various bone metabolic abnormalities associated with ESKD as definite risk factors for mortality, cardiovascular disease, increased risk of fractures, and other musculoskeletal complications grows stronger, the therapeutic agents to deal with these abnormalities continue to keep us on edge (Table 1).

Reasons for skepticism among nephrologists regarding novel drugs for MBD

MBD = mineral bone disease

In recent years, a few novel agents have
Save